To investigate further the changes of immune-related features associated with resistance to AI by duration of neoadjuvant endocrine therapy, two immune-related module scores were calculated: (i) The “durvalumab signature” (median of PD-L1, LAG3, CXCL9), previously reported to predict response to immunotherapy in melanoma (20) and (ii) the “immune-tolerance signature” (median of PD-L1, LAG3, IDO1), a module score reported by M.Ellis group as associated with resistance to AI in Luminal B tumors in the neoadjuvant setting (19). The gene discussed is CXCL9; the disease is melanoma.